KRAS and neoplasm: A recent study by Li et al. suggested that NOZ gallbladder cancer cells are responsive to ERBB2 inhibitors based on ectopic expression of mutant ERBB2 constructs.19 However, we believe that the evidence presented in our study argues for ERBB2 inhibitors as unlikely to be relevant among gallbladder cancer, such as NOZ tumor cells, that harbor KRAS G12V mutation.